)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Arcturus Therapeutics (ARCT) investor relations material
Arcturus Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Aug, 2025
Executive summary
Advanced Phase II trials for inhaled mRNA therapy in cystic fibrosis and OTC deficiency, with positive interim data and ongoing enrollment; regulatory filings for KOSTAIVE® in the UK, Japan, and US progressing, with approvals anticipated in late 2025 and 2026.
Achieved key regulatory milestones for KOSTAIVE, the first approved self-amplifying mRNA COVID-19 vaccine, with commercial launches in Japan and Europe and a marketing application filed in the UK.
Next-generation flu and pandemic influenza vaccine candidates advanced in clinical trials, with promising safety and immunogenicity data; ARCT-2304 received FDA Fast Track Designation.
Restructuring and pipeline focus, along with CSL Seqirus collaboration, extended cash runway into 2028, supporting ongoing clinical and commercial activities.
Appointment of Dr. Moncef Slaoui as Chairman of the Board effective July 1, 2025.
Financial highlights
Q2 2025 revenue was $28.3M, down over 40% year-over-year, mainly due to lower CSL collaboration revenue as KOSTAIVE transitioned to commercial phase.
Q2 2025 operating expenses were $39.9M, down from $71M in Q2 2024; six-month operating expenses were $86M, down from $139M.
R&D expenses for Q2 2025 were $29.6M, down from $58.7M year-over-year, reflecting lower manufacturing and clinical costs.
Net loss for Q2 2025 was $9.2M ($0.34/share), improved from $17.2M ($0.64/share) in Q2 2024.
Cash, cash equivalents, and restricted cash totaled $253.4M as of June 30, 2025, supporting operations into 2028.
Outlook and guidance
Interim Phase II data for cystic fibrosis program expected in September 2025, with full study enrollment by year-end and Phase III initiation targeted for 2026.
Regulatory alignment for OTC deficiency and KOSTAIVE programs expected in 2026, with approvals anticipated in major markets.
General and administrative expenses expected to decrease slightly over the next twelve months; continued focus on CF, OTC, and vaccine programs.
What FEV bar is sufficient for ARCT032?
OTC: Biomarker use for Phase 3 alignment?
How did pipeline focus extend cash runway?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arcturus Therapeutics earnings date
Q3 20256 Nov, 2025
Next Arcturus Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing RNA-based therapeutics for the treatment of infectious diseases, rare diseases, and other medical conditions. The company utilizes its proprietary self-amplifying mRNA technology and lipid nanoparticle delivery system to develop vaccines and therapies. Arcturus' pipeline includes treatments for diseases such as COVID-19 and other RNA-based therapies targeting unmet medical needs. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage